Delving into the Latest Updates on Hangzhou Tianji Jishi Biotechnology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Founded in August 2021, Tianji Jishi is dedicated to advancing mitochondrial research to promote global health. With a vision to emerge as a leader in innovative biopharmaceuticals, they pursue multiple concurrent R&D pipelines focused on novel small molecule selective mitophagy inducers and tumor immunoenhancers.

Tags

Nervous System Diseases

Congenital Disorders

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

TEAD(TEA domain transcription factors)	1

Primary objective To evaluate the effectiveness of TJ0113 capsules in the treatment of early PD patients. Secondary objective To evaluate the effectiveness of TJ0113 capsules in the treatment of early PD patients; To evaluate the safety of TJ0113 capsules in the treatment of early PD patients. Exploratory objective To explore the changes in inflammatory indicators in patients with early PD treated with TJ0113 capsules.

Start Date18 Sep 2024

Sponsor / Collaborator

Hangzhou Tianji Jishi Biotechnology Co., Ltd.Startup

NCT06596005

/ RecruitingPhase 2IIT

A Randomized, Double-blind, Placebo Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsule in Patients with Early-stage Parkinson's Disease

A randomized, double-blind, placebo parallel-controlled Phase II clinical trial to evaluate the efficacy and safety of TJ0113 capsule in patients with early-stage Parkinson's disease

Start Date18 Sep 2024

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

[+3]

CTR20232426

/ CompletedPhase 1

一项评价TJ0113胶囊在健康受试者中单次、多次及餐后口服给药后的安全性、耐受性和药代动力学的Ⅰ期临床试验

[Translation] A Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TJ0113 capsules after single, multiple, and postprandial oral administration in healthy subjects

主要目的：评价TJ0113胶囊单次、多次、标准高脂饮食后，口服给药后的安全性和耐受性。次要目的：评价TJ0113胶囊单次、多次、标准高脂饮食后，口服给药后的药代动力学特征；探索性目的：探索TJ0113胶囊单次、多次、标准高脂饮食后，口服给药后的生物表征。

[Translation]

Primary purpose: To evaluate the safety and tolerability of TJ0113 capsules after single, multiple, and standard high-fat diet oral administration. Secondary purpose: To evaluate the pharmacokinetic characteristics of TJ0113 capsules after single, multiple, and standard high-fat diet oral administration; Exploratory purpose: To explore the biological characterization of TJ0113 capsules after single, multiple, and standard high-fat diet oral administration.

Start Date04 Aug 2023

Sponsor / Collaborator

Hangzhou Tianji Jishi Biotechnology Co., Ltd.Startup

100 Clinical Results associated with Hangzhou Tianji Jishi Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Hangzhou Tianji Jishi Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Hangzhou Tianji Jishi Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Hangzhou Tianji Jishi Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 2 Clinical

Login to view more data